The receptor for advanced glycation endproducts and its ligands in patients with myasthenia gravis

Biochemical and Biophysical Research Communications

Volumn 420, Issue 1, 2012, Pages 96-101

  Moser, Bernhard ^a   Bekos, Christine ^a   Zimprich, Fritz ^a   Nickl, Stefanie ^a,b   Klepetko, Walter ^a   Ankersmit, Jan ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b INSTITUTE FOR MICROELECTRONICS   (Austria)

Author keywords

Autoimmunity; Myasthenia gravis; RAGE ligands; Receptor for advanced glycation endproducts

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CALGRANULIN A; CHOLINERGIC RECEPTOR; PROTEIN S100B;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH MOBILITY GROUP BOX DOMAIN; HUMAN; MALE; MYASTHENIA GRAVIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; CROSS-SECTIONAL STUDIES; FEMALE; HMGB1 PROTEIN; HUMANS; LIGANDS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; PROTEIN ISOFORMS; RECEPTORS, CHOLINERGIC; RECEPTORS, IMMUNOLOGIC; YOUNG ADULT;

EID: 84859103545     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.02.121     Document Type: Article

References (24)

1. Phillips L.H. The epidemiology of myasthenia gravis. Ann. N.Y. Acad. Sci. 2003, 998:407-412.
2. Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat. Rev. Immunol. 2002, 2(10):797-804.
3. Schmidt A.M., Vianna M., Gerlach M., et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J. Biol. Chem. 1992, 267(21):14987-14997.
4. Taguchi A., Blood D.C., del Toro G., et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000, 405(6784):354-360.
5. Voll R.E., Urbonaviciute V., Fürnrohr B., et al. The role of high-mobility group box 1 protein in the pathogenesis of autoimmune diseases. Curr. Rheumatol. Rep. 2008, 10(5):341-342.
6. U. Andersson, H.E. Harris, The role of HMGB1 in the pathogenesis of rheumatic disease, Biochim. Biophys. Acta 1799 (1-2) (2010) 141-148 (Review).
7. Leclerc E., Sturchler E., Vetter S.W. The S100B/RAGE axis in Alzheimer's disease. Cardiovasc. Psychiatry Neurol. 2010, 2010:539581.
8. A.J. Halayko, S. Ghavami, S100A8/A9: a mediator of severe asthma pathogenesis and morbidity? Can. J. Physiol. Pharmacol. 87 (10) (2009) 743-755 (Review).
9. B. Moser, B.I. Hudson, A.M. Schmidt, Soluble RAGE: a hot new biomarker for the hot joint? Arthritis Res Ther. 7 (4) (2005) 142-144.
10. Kalea A.Z., Schmidt A.M., Hudson B.I. Alternative splicing of RAGE: roles in biology and disease. Front Biosci. 2011, 1(17):2756-2770.
11. Moser B., Szabolcs M.J., Ankersmit H.J., et al. Blockade of RAGE suppresses alloimmune reactions in vitro and delays allograft rejection in murine heart transplantation. Am. J. Transplant. 2007, 7(2):293-302. (Erratum in Am. J. Transplant. 7 (5) (2007) 1318).
12. Moser B., Desai D.D., Downie M.P., et al. Receptor for advanced glycation end products expression on T cells contributes to antigen-specific cellular expansion in vivo. J. Immunol. 2007, 179(12):8051-8058.
13. Chen Y., Yan S.S., Colgan J., et al. Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products. J. Immunol. 2004, 173(2):1399-1405.
14. Pullerits R., Bokarewa M., Dahlberg L., et al. Decreased levels of soluble receptor for advanced glycation endproducts in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res. Ther. 2005, 7:R817-R824.
15. Ma C.Y., Jiao Y.L., Zhang J., et al. Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-alpha and TNF-alpha in systemic lupus erythematosus. Rheumatol. Int. 2012, 32(2):395-402.
16. Urbonaviciute V., Voll R.E. High-mobility group box 1 represents a potential marker of disease activity and novel therapeutic target in systemic lupus erythematosus. J. Intern. Med. 2011, 270(4):309-318.
17. Ahmed M.U., Thorpe S.R., Baynes J.W. Identification of N epsilon-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J. Biol. Chem. 1986, 261:4889-4894.
18. Vlassara M., Bucala R., Striker L. Pathogenetic effects of advanced glucosylation: biochemical, biologic and clinical implications for diabetes and aging. Lab. Invest. 1994, 70:138-151.
19. Virella G., Thorpe S.R., Alderson N.L., et al. Autoimmune response to advanced glycosylation end-products of human LDL. J. Lipid Res. 2003, 44(3):487-493.
20. Yan S.S., Wu Z.Y., Zhang H.P., et al. Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat. Med. 2003, 9(3):287-293.
21. D. Foell, H. Wittkowski, T. Vogl, et al., S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules, J. Leukoc. Biol. 81 (1) (2007) 28-37 (Review).
22. Mu L., Zhang Y., Sun B., et al. Activation of the receptor for advanced glycation end products (RAGE) exacerbates experimental autoimmune myasthenia gravis symptoms. Clin. Immunol. 2011, 141:36-48.
23. Bierhaus A., Schiekofer S., Schwaninger M., et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001, 50(12):2792-2808.
24. Aarli J.A. Late-onset myasthenia gravis: a changing scene. Arch. Neurol. 1999, 56(1):25-27.